SCHEMBL5341814

SCHEMBL5341814

Cc1cnc(N)c2nc(C)n(CCCCCS(=O)(=O)c3ccc(F)cc3F)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.36
HASPIN Q8TF76 1/20 0.34
ALOX5AP P20292 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
PIK3CB P42338 1/20 0.32
PIK3CA P42336 5/20 0.32
FEN1 P39748 1/20 0.32
PIK3C3 Q8NEB9 1/20 0.31
MAPK14 Q16539 1/20 0.31
MGAT2 Q10469 1/20 0.31
GAK O14976 1/20 0.30
ABL1 P00519 1/20 0.30
EPHA1 P21709 1/20 0.30
EPHA2 P29317 1/20 0.30
EPHA3 P29320 1/20 0.30
EPHB2 P29323 1/20 0.30
MAPK8 P45983 1/20 0.30
EPHB3 P54753 1/20 0.30
EPHB4 P54760 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4792949 0.99 CA2 (0.36) CA2HASPINALOX5APALDH1A1MAPT
SCHEMBL4793044 0.96 ALOX5AP (0.36) CA2HASPINALOX5APALDH1A1MAPT
SCHEMBL5337200 0.90 TLR7 (0.38) CA2HASPINALOX5APALDH1A1MAPT
SCHEMBL4791320 0.89 TLR7 (0.39) CA2HASPINALOX5APALDH1A1MAPT
SCHEMBL5343016 0.88 TLR7 (0.36) CA2HASPINALOX5APPIK3CAFEN1
SCHEMBL4790933 0.88 TLR7 (0.41) ALOX5APFEN1
SCHEMBL4790566 0.87 TLR7 (0.36) CA2HASPINALOX5APPIK3CAFEN1
SCHEMBL4793675 0.87 TLR7 (0.42)
SCHEMBL4793247 0.86 TLR8 (0.37) CA2ALOX5APFEN1
SCHEMBL4792102 0.86 PIK3CA (0.32) CA2HASPINALOX5APPIK3CAFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 CA2 4028/4885HASPIN 993/4885ALOX5AP 1981/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP CA2 3778/4885HASPIN 829/4885ALOX5AP 1093/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 CA2 4028/4885HASPIN 993/4885ALOX5AP 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.